Dolutegravir metabolic effects

Effects of Dolutegravir on the Body: A Comprehensive Analysis

Dolutegravir (DTG) is a second-generation integrase strand transfer inhibitor (INSTI) that works by inhibiting HIV integrase through binding to the active site and blocking viral DNA integration into host cells[1][2][3]. While generally well-tolerated, DTG produces a complex array of effects throughout the body, affecting multiple organ systems and cellular processes.

Central Nervous System and Blood-Brain Barrier Effects

**Blood-Brain Barrier Penetration and CNS Distribution**

Dolutegravir demonstrates significant ability to cross the blood-brain barrier, with cerebrospinal fluid (CSF) concentrations reaching 9.6-18 ng/mL, which are similar to unbound plasma concentrations[4][5][6]. The CSF-to-plasma ratio ranges from 0.19-5.11%, with all patients achieving therapeutic concentrations well above the required inhibitory concentration for wild-type HIV (0.2 ng/mL)[5][6]. Importantly, DTG penetration correlates with blood-brain barrier permeability, with increased barrier permeability associated with higher CSF drug diffusion[6].

**Neuropsychiatric Effects**

Clinical studies reveal substantial central nervous system effects, with neuropsychiatric adverse events occurring in 3.5% of patients (range 1.4-7.2%) leading to treatment discontinuation[7][8][9]. The most common symptoms include insomnia, dizziness, nervousness, depression, headache, reduced concentration, and other unexplained pain[8][9]. Post-marketing surveillance indicates higher rates of CNS side effects compared to clinical trials, particularly affecting women, patients over 60, and those starting abacavir simultaneously[10].

**Blood-Brain Barrier Integrity**

Research demonstrates that dolutegravir disrupts blood-brain barrier integrity by downregulating tight junction proteins (TJP1, OCLN, CLDN5) and upregulating pro-inflammatory cytokines (IL6, IL8, IL1β)[11]. When combined with sertraline, DTG significantly reduces barrier integrity and increases permeability, potentially contributing to neuropsychiatric adverse events[4].

Mitochondrial and Cellular Effects

**Mitochondrial Function Disruption**

Dolutegravir produces significant mitochondrial toxicity in multiple cell types. In human fibroblasts, DTG-containing regimens increase apoptosis, mitochondrial reactive oxygen species (mtROS), mitochondrial mass, and induce fragmented mitochondrial networks compared to non-DTG regimens[12]. These effects are fully reversible upon drug discontinuation but suggest substantial mitochondrial stress during treatment[12].

**Cellular Metabolic Impact**

In neuroblastoma cells, DTG affects mitochondrial protein expression levels and ATP synthase function[13][14]. Cell-type specific responses occur, with DTG decreasing mitochondrial activity in epithelial cells while paradoxically increasing ATP generation and REDOX activity in microglial cells[15]. The drug also inhibits autophagy function in brain microvascular endothelial cells, potentially affecting cellular waste clearance mechanisms[16].

**Cellular Stress Response Activation**

DTG exposure activates the integrated stress response (ISR) in neural development models, leading to upregulation of stress-related genes including ATF4 targets DDIT3 (CHOP), TNFRSF10B (DR5), and SESN2[17]. This activation disrupts cell cycle progression through increased P21 expression and affects neurogenesis by reducing neural stem cells and postmitotic neurons[17].

Renal System Effects

**Creatinine Elevation**

The most consistent biochemical effect of dolutegravir is serum creatinine elevation, typically occurring within one week of initiation and plateauing at an average increase of 11 mmol/L (0.1-0.2 mg/dL)[1][18][19]. This elevation results from inhibition of renal transporters OCT-2 (organic cation transporter 2) and MATE-2K (multidrug and toxin extrusion protein), which reduces creatinine secretion without affecting actual glomerular filtration rate[18][20][19].

**Renal Function Assessment**

Despite creatinine elevation, measured GFR using iohexol clearance shows no significant change, confirming that the creatinine rise is non-pathological[20]. However, this effect can complicate clinical assessment of kidney function, particularly in transplant recipients or patients with existing renal impairment[18].

Hepatic Effects

**Liver Function Impact**

Hepatotoxicity is a rare but serious adverse effect, with transaminase elevations occurring in approximately 5% of patients[1]. In patients with hepatitis B or C coinfection, the incidence rises to 16%, likely reflecting immune reconstitution effects[1]. Severe cases of drug-induced liver injury leading to sub-acute liver failure requiring transplantation have been reported, though extremely rare[21][22][23].

**Metabolic Processing**

Dolutegravir is metabolized predominantly through hepatic glucuronidation by UDP-glucuronosyltransferase 1A1, with minimal urinary excretion[1][3]. Approximately 64% is eliminated in feces, and the drug shows minimal interaction with major cytochrome P450 enzymes[2][20].

Cardiovascular System Effects

**Blood Pressure and Cardiovascular Risk**

Meta-analyses of randomized trials show no significant effect of dolutegravir on cardiovascular serious adverse events or blood pressure changes[24][25]. However, some observational studies report mixed findings, with conflicting evidence regarding hypertension risk depending on the comparator drugs and study populations[25].

**Cardiovascular Biomarkers**

Studies examining cardiovascular biomarkers show complex effects. While DTG may reduce "bad" LDL cholesterol by 7.7%, biomarker analyses reveal mixed cardiovascular signals, with some markers suggesting benefit (decreased sCD14) while others suggest potential harm (decreased adiponectin)[26].

Metabolic and Weight Effects

**Weight Gain and Adipose Tissue Changes**

Dolutegravir causes significant weight gain through direct effects on adipose tissue. The drug promotes adipocyte differentiation, increases lipid storage markers, and induces adipose tissue fibrosis by upregulating collagen proteins[27]. Mechanistic studies suggest DTG inhibits melanocortin-4 receptor (MC4R) activity, disrupting energy homeostasis and appetite regulation[27].

**Metabolic Consequences**

Weight gain leads to increased incidence of hyperglycemia, hypertension, and metabolic syndrome[27]. DTG-exposed adipocytes show higher lipid accumulation, lower leptin and adiponectin levels, and reduced glucose uptake compared to controls[27].

Immune System Effects

**CD4+ T-Cell Recovery**

Dolutegravir demonstrates excellent immunological efficacy, with significant increases in CD4+ T-cell counts. Studies show median increases from baseline of 169 cells/μL at 6 months, with recovery rates of approximately 28 cells/μL per month[28][29]. The drug shows superior CD4+ recovery compared to some alternative regimens[28].

**Viral Suppression**

DTG achieves high rates of viral suppression, with 79.8% and 91.7% of patients achieving HIV-1 RNA <50 copies/mL at 3 and 6 months, respectively[29]. The drug maintains effective antiviral activity across multiple tissue compartments[30].

Bone and Musculoskeletal Effects

**Bone Mineral Density**

Unlike many antiretroviral drugs, dolutegravir appears to have positive effects on bone health. Studies show significant improvements in lumbar spine bone mineral density, with increases of 1.6% over 102 weeks[31]. Patients with osteopenia or osteoporosis at baseline experience particularly pronounced improvements[31][32].

**Bone Safety Profile**

DTG-containing regimens reduce the negative impact of antiretroviral therapy on bone, especially when combined with abacavir/lamivudine rather than tenofovir-containing regimens[31]. The bone-protective effects are most pronounced in dual therapy combinations[32][33].

Gastrointestinal Effects

**Common GI Symptoms**

Gastrointestinal effects include nausea, diarrhea, and gas, though these are generally mild and self-limiting[34][35]. Rare cases of severe drug-induced colitis have been reported, characterized by diarrhea, urgency, and histological evidence of apoptotic crypt epithelial injury[36].

**Food Effects**

Food increases dolutegravir exposure by 33-66% depending on fat content, but this increase is not considered clinically significant[37]. Unlike some other integrase inhibitors, DTG can be taken with or without food without major dosing adjustments[37].

Conclusion

Dolutegravir produces wide-ranging effects throughout the body, from significant CNS penetration and neuropsychiatric effects to mitochondrial disruption and metabolic changes. While generally well-tolerated with excellent antiviral efficacy, the drug's complex pharmacological profile requires careful monitoring for weight gain, neuropsychiatric symptoms, and potential, though rare, serious adverse effects including severe hepatotoxicity. The drug's ability to cross the blood-brain barrier effectively makes it valuable for CNS HIV suppression but also contributes to its neuropsychiatric side effect profile.

Sources

[1] Dolutegravir – a review of the pharmacology, efficacy, and safety in ... https://pmc.ncbi.nlm.nih.gov/articles/PMC4500604/

[2] Dolutegravir: Uses, Interactions, Mechanism of Action - DrugBank https://go.drugbank.com/drugs/DB08930

[3] [Mechanisms of action, pharmacology and interactions of dolutegravir] https://pubmed.ncbi.nlm.nih.gov/25858605/

[4] Effect of Dolutegravir and Sertraline on the Blood Brain Barrier (BBB) https://pmc.ncbi.nlm.nih.gov/articles/PMC7141951/

[5] A Study of the Pharmacokinetics and Antiviral Activity of Dolutegravir ... https://pmc.ncbi.nlm.nih.gov/articles/PMC4166983/

[6] Dolutegravir Cerebrospinal Fluid Diffusion in HIV-1–Infected ... https://pmc.ncbi.nlm.nih.gov/articles/PMC6546201/

[7] Central nervous system disorders after use of dolutegravir https://pmc.ncbi.nlm.nih.gov/articles/PMC10539422/

[8] Further reports of CNS-related side effects with dolutegravir https://i-base.info/htb/30853

[9] [PDF] Neuropsychiatric Adverse Events with Dolutegravir and Other ... https://www.natap.org/2023/HIV/aids_21_1_04-10.pdf

[10] Dolutegravir and central nervous system side-effects: abacavir, older ... https://www.aidsmap.com/news/oct-2016/dolutegravir-and-central-nervous-system-side-effects-abacavir-older-age-increase-risk

[11] Antiretroviral drugs efavirenz, dolutegravir and bictegravir ... - Frontiers https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2023.1118580/full

[12] Dolutegravir-containing HIV therapy reversibly alters mitochondrial ... https://pubmed.ncbi.nlm.nih.gov/36399361/

[13] [PDF] Effect Of Antiretroviral Drug Dolutegravir On Mitochondrial Function https://elischolar.library.yale.edu/cgi/viewcontent.cgi?article=1922&context=ysphtdl

[14] Effect Of Antiretroviral Drug Dolutegravir On Mitochondrial Function https://elischolar.library.yale.edu/ysphtdl/1928/

[15] Physiologically Relevant Concentrations of Dolutegravir ... - PubMed https://pubmed.ncbi.nlm.nih.gov/34093527/

[16] Dolutegravir Inhibits Autophagy In Vitro in a Mouse Blood–Brain ... https://pmc.ncbi.nlm.nih.gov/articles/PMC12180569/

[17] Exposure to the antiretroviral drug dolutegravir impairs structure and ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11576471/

[18] Serum creatinine elevation after switch to dolutegravir in a human ... https://pmc.ncbi.nlm.nih.gov/articles/PMC5525135/

[19] Comparison of renal function biomarkers | IDR - Dove Medical Press https://www.dovepress.com/comparison-of-renal-function-biomarkers-of-serum-creatinine-and-cystat-peer-reviewed-fulltext-article-IDR

[20] Renal effects of non-tenofovir antiretroviral therapy in patients living ... https://pmc.ncbi.nlm.nih.gov/articles/PMC5866095/

[21] [PDF] Dolutegravir induced sub-acute hepatic failure in HIV positive ... https://www.sciedupress.com/journal/index.php/crim/article/download/15178/10166

[22] Dolutegravir-induced liver injury leading to sub-acute liver failure ... https://pubmed.ncbi.nlm.nih.gov/29059031/

[23] [PDF] Presumed Severe Hepatocellular Toxicity after Initiation on a ... https://www.anncaserep.com/open-access/presumed-severe-hepatocellular-toxicity-after-initiation-on-a-dolutegravir-based-hiv-8383.pdf

[24] Risks of cardiovascular or central nervous system adverse events ... https://pubmed.ncbi.nlm.nih.gov/29278532/

[25] Post hoc Analysis of the 48-week Randomised Second-line Switch ... https://academic.oup.com/cid/article/80/4/889/7908582

[26] Mixed Signals With Cardiovascular Markers in Dolutegravir Switch ... https://www.natap.org/2018/GLASGOW/GLASGOW_12.htm

[27] A review of dolutegravir-associated weight gain and secondary ... https://pmc.ncbi.nlm.nih.gov/articles/PMC11179510/

[28] Immunological efficacy and the impact on weight of dolutegravir-based https://www.dovepress.com/immunological-efficacy-and-the-impact-on-weight-of-dolutegravir-based--peer-reviewed-fulltext-article-IDR

[29] Dolutegravir based therapy showed CD4+ T cell count recovery and ... https://pmc.ncbi.nlm.nih.gov/articles/PMC10853173/

[30] Varying dolutegravir distribution across the body may affect the ... https://www.aidsmap.com/news/mar-2024/varying-dolutegravir-distribution-across-body-may-affect-drugs-ability-suppress-hiv

[31] Bone Safety of Dolutegravir-Containing Regimens in People Living ... https://pmc.ncbi.nlm.nih.gov/articles/PMC7368553/

[32] [PDF] Changes in bone mineral density in HIV-positive, virologically ... https://infezmed.it/media/journal/Vol_26_4_2018_6.pdf

[33] Clinical evidence review of dolutegravir-rilpivirine for treating human ... https://www.england.nhs.uk/wp-content/uploads/2020/03/1806-Evidence-Review.pdf

[34] Dolutegravir and Lamivudine: MedlinePlus Drug Information https://medlineplus.gov/druginfo/meds/a619043.html

[35] dolutegravir (Tivicay, Tivicay PD) https://www.iapac.org/fact-sheet/dolutegravir-tivicay-tivicay-pd/

[36] Dolutegravir-induced colitis in an HIV-infected patient https://academic.oup.com/jac/article/71/1/281/2363816

[37] Effect of Food on the Pharmacokinetics of the Integrase Inhibitor ... https://pmc.ncbi.nlm.nih.gov/articles/PMC3294934/

[38] Dolutegravir - a review of the pharmacology, efficacy, and ... - PubMed https://pubmed.ncbi.nlm.nih.gov/26185421/

[39] Dolutegravir - Wikipedia https://en.wikipedia.org/wiki/Dolutegravir

[40] Post-marketing safety concerns with dolutegravir - Frontiers https://www.frontiersin.org/journals/pharmacology/articles/10.3389/fphar.2025.1625601/full

[41] Risks & Side Effects of DOVATO (dolutegravir/lamivudine) https://www.dovato.com/dovato-side-effects/

[42] Population pharmacokinetics of dolutegravir: influence of drug–drug ... https://academic.oup.com/jac/article/74/9/2690/5497436

[43] Dolutegravir (oral route) - Side effects & dosage - Mayo Clinic https://www.mayoclinic.org/drugs-supplements/dolutegravir-oral-route/description/drg-20061287

[44] [PDF] TRIUMEQ (dolutegravir, abacavir and lamivudine) film-coated tablets https://viivhealthcare.com/content/dam/cf-viiv/viivhealthcare/en_AU/files/au-pi-triumeq.pdf

[45] Central nervous system disorders after use of dolutegravir - PubMed https://pubmed.ncbi.nlm.nih.gov/37605102/

[46] Cognitive performance, neuropsychiatric symptoms, and ... https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(24)00209-1/fulltext

[47] a prospective cohort study - The Lancet HIV https://www.thelancet.com/journals/lanhiv/article/PIIS2352-3018(24)00209-1/abstract

[48] Cardiometabolic Parameters 3 Years After Switch to Dolutegravir ... https://academic.oup.com/ofid/article/10/7/ofad359/7223126

[49] HIV-1 Resistance to Dolutegravir Is Affected by Cellular Histone ... https://journals.asm.org/doi/10.1128/jvi.00912-17

[50] Effect of dolutegravir-based antiretroviral therapy on glycemic ... https://www.nature.com/articles/s41598-025-02130-8

[51] Anti-HIV Drugs Cause Mitochondrial Dysfunction in Monocyte ... https://journals.asm.org/doi/10.1128/aac.01941-21

[52] Determinants of early change in serum creatinine after initiation of ... https://bpspubs.onlinelibrary.wiley.com/doi/10.1111/bcp.16009

[53] ViiV Healthcare announces phase III study meets primary endpoint ... https://viivhealthcare.com/hiv-news-and-media/news/press-releases/2019/july/viiv-healthcare-announces-phase-iii-study-meets-primary-endpoint/

[54] Studies on dolutegravir and sleep, cardiovascular and CNS side ... https://i-base.info/htb/32830